915Indexed trials
mesh condition
Alzheimer Disease
Intelligence
Alzheimer Disease intelligence: 915 indexed trials, 196 recruiting studies, 514 sponsors across 60 countries.
196Recruiting
514Sponsors
60Countries
Leading sponsors
Avid Radiopharmaceuticals140 recruiting
Massachusetts General Hospital143 recruiting
Eli Lilly and Company123 recruiting
Pfizer110 recruiting
Johns Hopkins University104 recruiting
National Institute on Aging (NIA)101 recruiting
Merck Sharp & Dohme LLC101 recruiting
Wyeth is now a wholly owned subsidiary of Pfizer90 recruiting
Hoffmann-La Roche91 recruiting
National Taiwan University Hospital92 recruiting
Bristol-Myers Squibb82 recruiting
Indiana University82 recruiting
Geographic activity
United States445trials
France109trials
Canada85trials
United Kingdom71trials
Spain63trials
Germany56trials
Italy55trials
Australia50trials
Sweden42trials
South Korea41trials
Netherlands39trials
China38trials
Leading interventions
Donepezil15trials
florbetapir F 188trials
Memantine7trials
MRI6trials
Flortaucipir F184trials
donepezil4trials
Gantenerumab4trials
Donanemab4trials
Exercise4trials
BMS-7081634trials
SAM-5314trials
Bryostatin 13trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.